LNSMGD

LNSMGQD is a peptide that targets the adhesion interface of desmoglein DSG1 and DSG3, and interferes with the DSG trans-interaction single peptide (SP) component. LNSMGQD blocks autoantibody-induced loss of DSG trans-interactions by binding to DSGs, inhibiting p38 MAPK activation and keratin filament retraction. LNSMGQD can be used to study autoimmune skin diseases such as pemphigus vulgaris[1].

1152066-26-6

12352209

P38 MAPK

MAPK/ERK Pathway

COVID-19-immunoregulation

Inflammation/Immunology

99.92

O=C(N[C@@H](CC(N)=O)C(N[C@@H](CO)C(N[C@@H](CCSC)C(NCC(N[C@@H](CCC(N)=O)C(N[C@@H](CC(O)=O)C(O)=O)=O)=O)=O)=O)=O)[C@H](CC(C)C)N

C29H49N9O13S

763.82

[1]Spindler V, et al. Peptide-mediated desmoglein 3 crosslinking prevents pemphigus vulgaris autoantibody-induced skin blistering. J Clin Invest. 2013 Feb;123 (2) :800-11.

Blue Ice

-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)

http://file.medchemexpress.com/batch_PDF/HY-P11017/LNSMGQD-SDS-MedChemExpress.pdf

Peptides

No Development Reported